Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 386

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 386
---
 except as so modified or superseded, to constitute a part of this prospectus. This prospectus incorporates by reference the documents listed below:

| (1) | the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on April 30, 2025, which contains our audited consolidated financial statements for the most recent fiscal year for which those statements have been filed; |
| (2) | the Company’s Current Reports on Form 6-K and 6-K/A, filed with the SEC on July 22, 2025, September 10, 2025, October 3, 2025, October 8, 2025, October 15, 2025 and October 16, 2025;                                                                               |
| (3) | the description of our Ordinary Shares contained in our Registration Statement on Form 8-A filed with the SEC on December 14, 2018, including any amendments and reports filed for the purpose of updating such description.                                         |

We will provide a copy of the documents we incorporate by reference, at no cost, to any person who receives this prospectus. To request a copy of any or all of these documents, you should write or telephone us at 17 Hanover Square, London W1S 1BN, United Kingdom, Attention: Ian Huen, Chief Executive Officer, +44 20 80929299. Additionally, copies of the documents incorporated herein by reference may be accessed at our website at www.aptorumgroup.com. The reference to our website address does not constitute incorporation by reference of the information contained on or accessible through our website, and you should not consider the contents of our website in making an investment decision with respect to our Class A Ordinary Shares. 239 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Offering On October 10, 2025, the Company entered into a certain securities purchase agreement (the “Purchase Agreement”) with certain non-affiliated institutional investors (the “Purchasers”) pursuant to which the Company agreed to sell (1) 1,000,000 Class A ordinary shares (the “Ordinary Shares”), and (2) in a concurrent private placement, restricted warrants to purchase an aggregate of up to 2,000,000 Ordinary Shares (the “Investor Warrants”), for aggregate gross proceeds of approximately $2 million (the “Offering”). The Company currently intends to use